# Mazdutide

A weekly injection approved in China for weight management in June 2025, and in no region this book covers.

Also called: IBI362, Xinermei
Source page: https://peplogue.com/peptides/mazdutide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: GLP-1 and glucagon receptors.
- What it changes: GLP-1 lowers appetite. Glucagon pushes the liver to burn fat.
- What people notice: Weight loss in trials in China. Stomach side effects are common.

## What the evidence shows

- **Weight loss and type 2 diabetes**: Supported. In a Chinese trial in people with diabetes and obesity, weight fell 10.3% at 32 weeks, against 6.0% on semaglutide at its 1 mg diabetes dose (DREAMS-3).

## Side effects and risks

- common: Mainly stomach and bowel side effects.
- unknown: Trial data come almost entirely from China.

Who should avoid it: Anyone outside China or a clinical trial. Product sold online elsewhere is unapproved.

## How it has been given in trials

Weekly injection under the skin, at doses set by the Chinese label.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**Where is mazdutide approved?**

Only in China, where it was approved for weight management in June 2025. It is not approved in any region this book covers, product sold online elsewhere is unapproved, and FDA named it in warning letters to research-use-only sellers in August 2026.

**Is mazdutide better than semaglutide?**

In a Chinese trial in people with diabetes and obesity (DREAMS-3), weight fell 10.3% at 32 weeks on mazdutide, against 6.0% on semaglutide at its diabetes dose. Further head-to-head trials are running.

**What are the side effects of mazdutide?**

Mainly stomach and bowel side effects. The trial data come almost entirely from China.

**Who makes mazdutide?**

Innovent Biologics, which licensed it from Eli Lilly.

## Sources

- Clinical Trials Arena: DREAMS-3 results (27 Oct 2025): https://www.clinicaltrialsarena.com/news/innovent-biologics-mazdutide-glp-1ra-phase-iii-dreams-3/
- ArentFox Schiff: FDA letters to research-use-only vendors (Sep 2026): https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy